| Document |
Document Title |
|
WO/2022/181550A1 |
The purpose of the present invention is to provide: an antibody capable of binding to N-protein of SARS-CoV-2; and a method for utilizing the antibody. Provided is an antibody capable of binding to SARS-CoV-2, which has at least one st...
|
|
WO/2022/180116A1 |
Composition comprising a combination of oleuropein or metabolite thereof and Vitamin B6 thereof are provided. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a...
|
|
WO/2022/181515A1 |
Provided is a novel combination therapy with PD-1 signal inhibition therapy. A pharmaceutical composition of the present invention contains a substance that can enhance a T cell receptor (TCR) signal, and is administered before, after, o...
|
|
WO/2022/181785A1 |
[Problem] To provide a hair growth agent which is a topical agent that promotes growth of hair shafts in scalp hair, beards, eyebrows, and/or eyelashes, that enhances expression of genes that contribute to hair restoration in dermal papi...
|
|
WO/2022/182958A1 |
The disclosure provides methods for rescuing defects caused by abnormal CDKL5 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a hyperpolarization-activated cyclic nu...
|
|
WO/2022/181153A1 |
The present invention provides an in vivo polyamine enhancer that is superior in the effect of increasing the in vivo polyamine concentration and that can be applied to food products, health food products, medicinal products, external pr...
|
|
WO/2022/181763A1 |
The present invention provides a pharmaceutical composition for the treatment or prevention of stress-related disorders, stress-induced anxiety disorders, or stress-related disorders or anxiety disorders associated with depression that i...
|
|
WO/2022/181786A1 |
[Problem] To provide a hair growth agent that is an external preparation which: promotes the growth of hair shafts in hair, beard, eyebrow, and/or eyelash; accelerates the expression of genes that contribute to hair growth in dermal papi...
|
|
WO/2022/181797A1 |
The present disclosure provides a therapy for diabetes that targets abnormal stem cells by using an HDAC inhibitor combined with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabet...
|
|
WO/2022/181219A1 |
Provided is a technology that, by identifying a cardiomyocyte marker, prevents or treats novel virus infectious diseases, as well as inflammatory diseases, delayed effects and complications, and also acute respiratory distress syndrome a...
|
|
WO/2022/181798A1 |
The present disclosure efficiently recovers growth factors from platelet-rich plasma and provides an activated growth factor mixture. The present disclosure provides a method for preparing a growth factor mixture from blood, wherein th...
|
|
WO/2022/176970A1 |
Provided is an anti-PAD4 antibody in which HCDR1 includes an amino acid sequence of SEQ ID NO: 1, HCDR2 includes an amino acid sequence of SEQ ID NO: 2, HCDR3 includes an amino acid sequence of SEQ ID NO: 3, LCDR1 includes an amino acid ...
|
|
WO/2022/176174A1 |
The present invention provides an immune cell activator containing hibiscus or a fermented extract thereof as an active ingredient. The present invention also provides an anti-aging agent characterized in that said anti-aging agent conta...
|
|
WO/2022/174882A1 |
The present invention relates to a compounds of general formula (I) inhibiting both lysophosphatidic acid receptor 1 (LPA1) and receptor 2 (LPA2), particularly the invention relates to compounds that are 5-membered heterocyclyl carbamate...
|
|
WO/2022/177280A1 |
The present invention relates to a novel compound that inhibits the mTOR signaling pathway, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention was ...
|
|
WO/2022/178423A1 |
The present invention includes compositions and methods for increasing longevity of a cell or organism comprising administering to the cell or organism a composition comprising a therapeutically effective amount of 2,4-Disulfonyl-N-Tert-...
|
|
WO/2022/177267A1 |
The present invention relates to a compound for suppressing nonsense-mediated mRNA decay (hereinafter referred to as "NMD") and a pharmaceutically acceptable salt thereof. The present invention aims to prevent or treat NMD-related diseas...
|
|
WO/2022/177019A1 |
The present invention provides a novel inhalant as a therapeutic agent for COVID-19. The present invention pertains to an inhalant characterized by having used therein cepharanthine and a steroid drug or the like.
|
|
WO/2022/177881A1 |
Provided herein are compositions and methods for targeting dermal white adipose tissue for hair follicle stimulation and regeneration.
|
|
WO/2022/176677A1 |
Provided is a novel material that exhibits a superior effect for muscle enhancement using a fatty acid. The present invention is a composition for muscle enhancement characterized by containing, as an active component, at least one sub...
|
|
WO/2022/177967A1 |
ADGRG1 activity was found to promote myelination by its activity in pre-myelinating oligodendrocytes. Interventions made at various points along the ADGRG1-mediated myelination process can promote myelination. ADGRG1 activators, RhoA act...
|
|
WO/2022/177516A1 |
The present invention relates nutritional powder compositions intented to benefit people who need nutritional therapy for hard-to-heal wounds.
|
|
WO/2022/177032A1 |
Provided is a pharmaceutical composition that increases osteoblasts in a subject, the pharmaceutical composition containing high-purity mesenchymal stem cells. The pharmaceutical composition is used in combination with hematopoietic stem...
|
|
WO/2022/177269A1 |
The present invention relates to a compound for inhibiting nonsense-mediated mRNA decay (hereinafter referred to as "NMD") or a pharmaceutically acceptably salt thereof. The present invention aims to prevent or treat an NMD-related disea...
|
|
WO/2022/178419A1 |
The disclosure features compositions and methods for the treatment of inner ear dysfunction, such as hearing loss or vestibular dysfunction, that reduce inflammatory or cell-mediated immune toxicity in the inner ear, thereby improving tr...
|
|
WO/2022/176754A1 |
[Problem] To provide a channelrhodopsin molecule that responds to light having a shorter wavelength (preferably 460 nm or shorter) and has a high photosensitivity. To provide a channelrhodopsin molecule having a high calcium ion permeabi...
|
|
WO/2022/176920A1 |
The present disclosure provides a composition for treating or preventing a disease (for example, an infection, an allergy, or an autoimmune disease). The present disclosure provides a composition, a medicinal drug, or a kit for treating ...
|
|
WO/2022/177029A1 |
The purpose of the present invention is to provide a composition for treating or preventing an infection (COVID19) caused by SARS-CoV-2. A method for screening for a drug having an inhibitory activity against a protease of SARS-CoV2 is e...
|
|
WO/2022/173923A1 |
Methods for the ophthalmic delivery of roflumilast. The inventors have made the surprising discovery that the administration of pharmaceutical compositions comprising roflumilast to the cornea preferentially delivers the drug laterally t...
|
|
WO/2022/174256A1 |
The present disclosure provides compounds, or their tautomers or pharmaceutically acceptable salts thereof, and their pharmaceutical compositions that can selectively activate Yes-associated protein 1 (YAP). YAP activators of the present...
|
|
WO/2022/173789A1 |
Various aspects of this patent document relate to the findings that cannabigerol ("CBG") and CBG derivatives are tumor necrosis factor alpha ("TNF-alpha") signaling pathway inhibitors that are effective to treat pain, inflammation, and o...
|
|
WO/2022/173315A1 |
The present disclosure generally relates to methods of and uses for treating Prader-Willi Syndrome (PWS) in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formulas I, II, III or IV,...
|
|
WO/2022/173861A1 |
Modified stem cells and methods of use for stem cell transplant are provided.
|
|
WO/2022/173006A1 |
The present invention provides a composition in which the absorption of a poorly-absorbable drug is markedly improved and which comprises an ionic liquid and the poorly-absorbable drug, said composition being characterized in that: the i...
|
|
WO/2022/173042A1 |
COVID-19 caused by a coronavirus SARS-CoV-2, cytokine release syndrome, cytokine release syndrome in a chimeric antigen receptor (CAR)-T therapy, sepsis, systemic inflammatory response syndrome, hemophagocytotic syndrome, macrophage acti...
|
|
WO/2022/172523A1 |
The present invention addresses the problem of providing a composition capable of maintaining, improving, or enhancing immune function by activating plasmacytoid dendritic cells (pDCs). Lactoferrin and/or a lactoferrin hydrolysate is inc...
|
|
WO/2022/173795A1 |
Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds are (3-aryl-1,2,4-oxadiazol-5-yl)-3,4-dihydro-2H-pyrano[2,3-b]py
ridines of structure (I), in which Ar is aryl or heteroaryl. The compounds disclose...
|
|
WO/2022/172037A1 |
The present invention relates to compounds of Formulas A-D, I-IV and Z, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or ...
|
|
WO/2022/170519A1 |
Disclosed are TRPM8 modulators as defined by formula (I) for achieving a cooling effect on skin and mucousa.
|
|
WO/2022/172511A1 |
The present invention provides a composition characterized by containing two or more selected from the group consisting of Bifidobacteria or culture solutions thereof, glutamic acid, or polymers or salts thereof, and rice bran-derived fe...
|
|
WO/2022/168341A1 |
Provided is a novel and/or improved means for immunostimulation. A composition, a food or beverage, an animal feed or a medicine, each comprising a resistant protein having an immunostimulatory effect. The immunostimulatory effect is to ...
|
|
WO/2022/168962A1 |
The present invention provides an agent for suppressing interleukin 31 (IL-31) production and a pharmaceutical composition containing the same. The present invention also provides a novel compound that is effective as an active ingredien...
|
|
WO/2022/168968A1 |
Heretofore, there has been no medicine or food medicament capable of particularly preventing or improving, among side effects caused by medication, peripheral neuropathy caused by anticancer drugs such as oxaliplatin. This agent for pr...
|
|
WO/2022/169946A1 |
The present disclosure provides methods and compositions for treating a condition associated with impaired lymphatic drainage.
|
|
WO/2022/168975A1 |
The present invention exhibits strong preventive effects and/or therapeutic effects with regard to inflammatory disorders and/or pain disorders by combining and administering glutathione trisulfide or a pharmaceutically-acceptable salt t...
|
|
WO/2022/166806A1 |
Provided is a novel CD271-based antigenic epitope peptide. The epitope peptide is: (1) located in SEQ ID NO.1; or (2) located in an amino acid sequence having at least 80% identity with the sequence SEQ ID NO.1 in (1), SEQ ID NO.1 contai...
|
|
WO/2022/169284A1 |
The present invention relates to a novel compound which enables additional hydrogen bonding with amino acids at specific positions of histone acetyltransferase (HAT) p300 through the structural analysis of HAT p300. The novel compound ac...
|
|
WO/2022/169822A1 |
Described herein are methods for predicting treatment response to glutamate modulating agents, selecting treatment comprising glutamate modulating agents, for, and treating subjects with glutamate modulating agents, in subjects with auti...
|
|
WO/2022/169004A1 |
The present invention relates to a composition for the prevention or treatment of ciliopathy and metabolic disorder, the composition comprising a novel pyrazole derivative that inhibits FABP4, as an active ingredient. The composition of ...
|
|
WO/2022/168650A1 |
Provided are a novel homocysteine derivative and a method for producing the same, a composition comprising the compound, and an anti-inflammatory agent comprising the compound and/or the composition. A compound represented by formula 1.
|
